Amplitude Surgical – Consolidated 9-Month Sales of €77.3 Million, up 4.0% at Constant Exchange Rates
21 Avril 2022 - 6:00PM
Business Wire
- Consolidated sales of €77.3 million, +4.0% at constant exchange
rates
- Sales from knee and hip activity stable, +0.1% at constant
exchange rates
- Further growth in Novastep’s activity, +29.9% at constant
exchange rates
Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible
for PEA-PME plans) (Paris:AMPLI), a leading French player on the
surgical technology market for lower-limb orthopedics, announces
its sales for the third quarter of its 2021-22 financial year.
Olivier Jallabert, Amplitude Surgical’s CEO, commented:
“During the first 9 months of our 2021-22 financial year, Amplitude
Surgical posted sales growth of 4.0% at constant exchange rates.
However, the Group’s business continued to be negatively affected
by the public health situation associated with the COVID-19
pandemic on a large part of its markets. Health restrictions and
cancelled operations, as well as the reduced availability of
operating rooms and medical staff, slowed the Group’s sales
momentum. In March, we saw a gradual return to a more normal level
of activity on the French market. Novastep, meanwhile, has
continued its development and accounts for approximately 16.4% of
Group sales, with growth of 29.9% over the period”.
Sales by activity
9M 2021-22
sales
31/03/2022
31/03/2021
Δ at current exchange
rates
Δ at constant exchange
rates
€ thousands - IFRS
Knee and hip activity
64,565
63,980
0.9%
0.1%
Feet and ankles (Novastep)
12,690
9,531
33.1%
29.9%
Total
77,255
73,511
5.1%
4.0%
Q3 2021-22
sales
31/03/2022
31/03/2021
Δ at current exchange
rates
Δ at constant exchange
rates
€ thousands - IFRS
Knee and hip activity
24,378
23,908
2.0%
0.7%
Feet and ankles (Novastep)
4,778
3,693
29.4%
24.9%
Total
29,156
27,602
5.6%
4.0%
Over the first 9 months of its 2021-22 financial year (to
end-March 2022), Amplitude Surgical recorded sales of €77.3
million, up 5.1% in actual terms and 4.0% at constant exchange
rates.
In the third quarter of its 2021-22 financial year (from January
to March 2022), Amplitude Surgical generated sales of €29.2
million, up 5.6% in actual terms and 4.0% at constant exchange
rates. During the quarter, the Group’s business was again
significantly impacted by the public health situation, and notably
the fifth wave of the COVID-19 pandemic in France and across Europe
in January and February.
- Knee and hip activity was stable, with sales up 0.9% in
actual terms and +0.1% at constant exchange rates, in line with the
level of activity seen during the first 6 months of the year.
Globally, the health situation observed over the period and the
lack of availability of operating rooms and medical staff are
continuing to have a substantial negative impact on activity.
- Novastep, innovative solutions for foot and ankle
surgery, recorded strong growth over the first 9 months of the
year, with sales totaling €12.7 million (+29.9% at constant
exchange rates). Novastep’s activity now accounts for 16.4% of all
Group sales.
Sales by geographical
region
9M 2021-22
sales
31/03/2022
31/03/2021
Δ at current exchange
rates
Δ at constant exchange
rates
€ thousands - IFRS
France
50,311
48,389
4.0%
4.0%
International
26,944
25,122
7.3%
3.9%
of which: Subsidiaries
20,811
19,215
8.3%
4.0%
of which: Distributors
6,133
5,907
3.8%
3.8%
Total
77,255
73,511
5.1%
4.0%
Q3 2021-22
sales
31/03/2022
31/03/2021
Δ at current exchange
rates
Δ at constant exchange
rates
€ thousands - IFRS
France
19,809
18,775
5.5%
5.5%
International
9,347
8,827
5.9%
0.7%
of which: Subsidiaries
6,986
6,758
3.4%
-3.4%
of which: Distributors
2,361
2,068
14.2%
14.1%
Total
29,156
27,602
5.6%
4.0%
From a geographical perspective, sales evolved as follows:
- On the French market, cumulative sales to the end of
March totaled €50.3 million, up 4.0%. Despite the posted growth,
activity continued to be negatively impacted by the health
situation associated with COVID-19 for most of the first 9 months
of the year. Since the start of March, the gradual improvement in
the public health situation in France has allowed a return to a
more normal level of activity. France accounted for 65% of total
Group sales;
- The Group’s international activity generated sales of
€26.9 million, up 7.3% in actual terms and 3.9% at constant
exchange rates thanks to the Group’s international subsidiaries.
The Group’s subsidiaries recorded sales growth of 8.3% in actual
terms to €20.8 million thanks to the considerable increase in
Novastep’s foot and ankle activity in the United States. Business
with the Group’s distributors increased by 3.8% to €6.1
million;
- Amplitude Surgical’s direct business (French market and
international subsidiaries), which accounted for almost 92% of the
Group’s total sales, generated growth of 4.0% at constant exchange
rates;
Next press release
2021-22 full-year sales, on Thursday July 21, 2022, after
market.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a
leading French player on the global surgical technology market for
lower-limb orthopedics. Amplitude Surgical develops and markets
high-end products for orthopedic surgery covering the main
disorders affecting the hip, knee and extremities, and notably foot
and ankle surgery. Amplitude Surgical develops, in close
collaboration with surgeons, numerous high value-added innovations
in order to best meet the needs of patients, surgeons and
healthcare facilities. A leading player in France, Amplitude
Surgical is developing abroad through its subsidiaries and a
network of exclusive distributors and agents distributing its
products in more than 30 countries. Amplitude Surgical operates on
the lower-limb market through the intermediary of its Novastep
subsidiaries in France and the United States. At June 30, 2021,
Amplitude Surgical had a workforce of 443 employees and recorded
sales of nearly 95.5 million euros.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220421005599/en/
Amplitude Surgical Dimitri Borchtch CFO finances@amplitude-surgical.com
+33 (0)4 75 41 87 41
NewCap Investor
Relations Mathilde
Bohin/Thomas Grojean amplitude@newcap.eu +33 (0)1 44 71 94
94
NewCap Media
Relations Nicolas
Merigeau amplitude@newcap.eu +33 (0)1 44 71 94 98
Amplitude Surgical (EU:AMPLI)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Amplitude Surgical (EU:AMPLI)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024